Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Dorr

Showing results (31-40 of 184) with videos related to

Pageof 19
Sort By:
Journal of Cancer Research and Clinical Oncology|January 1, 1988
Cimetidine enhances cisplatin toxicity in miceR T Dorr, M J Soble
Medical and Pediatric Oncology|January 1, 1979
Inapparent infiltrations associated with vindesine administrationR T Dorr, S E Jones
Research Communications in Chemical Pathology and Pharmacology|February 1, 1987
Lack of enhanced myelotoxicity with buthionine sulfoximine and sulfhydryl-dependent anticancer agents in miceM J Soble, R T Dorr
Cancer Drug Delivery|January 1, 1987
Schedule-dependent toxicity of tumor necrosis factor in rodentsJ D Liddil, R T Dorr
British Journal of Cancer|January 1, 1982
Cimetidine enhancement of cyclophosphamide antitumour activityR T Dorr, D S Alberts
Immunopharmacology|July 1, 1989
Effect of interferon, interleukin-2 and tumor necrosis factor on myocardial cell viability and doxorubicin cardiotoxicity in vitroR T Dorr, N G Shipp
Oncology Nursing Forum|May 1, 1991
Case report: topical DMSO for mitomycin-C-induced skin ulcerationD S Alberts, R T Dorr
Cancer Treatment Reviews|September 8, 2001
Drug interactions with the taxanes: clinical implicationsA F Baker, R T Dorr
European Journal of Cancer (Oxford, England : 1990)|January 1, 1996
Cardioprotection of rat heart myocytes with amifostine (Ethyol) and its free thiol, WR-1065, in vitroR T Dorr, K Lagel, S McLean
PDA Journal of Pharmaceutical Science and Technology|August 6, 2000
Approaches to reducing toxicity of parenteral anticancer drug formulations using cyclodextrinsR Bhardwaj, R T Dorr, J Blanchard
Pageof 19

Showing results (31-40 of 184) with videos related to

Sort By:
Pageof 19
Journal of Cancer Research and Clinical Oncology|January 1, 1988
Cimetidine enhances cisplatin toxicity in miceR T Dorr, M J Soble
Medical and Pediatric Oncology|January 1, 1979
Inapparent infiltrations associated with vindesine administrationR T Dorr, S E Jones
Research Communications in Chemical Pathology and Pharmacology|February 1, 1987
Lack of enhanced myelotoxicity with buthionine sulfoximine and sulfhydryl-dependent anticancer agents in miceM J Soble, R T Dorr
Cancer Drug Delivery|January 1, 1987
Schedule-dependent toxicity of tumor necrosis factor in rodentsJ D Liddil, R T Dorr
British Journal of Cancer|January 1, 1982
Cimetidine enhancement of cyclophosphamide antitumour activityR T Dorr, D S Alberts
Immunopharmacology|July 1, 1989
Effect of interferon, interleukin-2 and tumor necrosis factor on myocardial cell viability and doxorubicin cardiotoxicity in vitroR T Dorr, N G Shipp
Oncology Nursing Forum|May 1, 1991
Case report: topical DMSO for mitomycin-C-induced skin ulcerationD S Alberts, R T Dorr
Cancer Treatment Reviews|September 8, 2001
Drug interactions with the taxanes: clinical implicationsA F Baker, R T Dorr
European Journal of Cancer (Oxford, England : 1990)|January 1, 1996
Cardioprotection of rat heart myocytes with amifostine (Ethyol) and its free thiol, WR-1065, in vitroR T Dorr, K Lagel, S McLean
PDA Journal of Pharmaceutical Science and Technology|August 6, 2000
Approaches to reducing toxicity of parenteral anticancer drug formulations using cyclodextrinsR Bhardwaj, R T Dorr, J Blanchard
Pageof 19